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Relationship between rhinitis duration and
worsening of nasal function
Giorgio Ciprandi, MD, Ignazio Cirillo, MD, Angela Pistorio, MD,
and Stefania La Grutta, MD, Genoa, La Spezia, and Palermo, ItalyBACKGROUND: While it is well known that asthma is char-
acterized by airway remodeling, few studies instead have investi-
gated this issue in patients with allergic rhinitis (AR).
OBJECTIVE: The aim of the study was to evaluate nasal function,
ie, nasal airflow, in a cohort of patients with persistent AR (PER).
METHODS: One hundred patients, 50 with short-term and 50
with long-term PER, were prospectively and consecutively
evaluated, clinically evaluated by visit, skin prick test, and
rhinomanometry.
RESULTS: Nasal airflow values were significantly lower (median
flow: 348 mL/sec) in patients with long-term rhinitis (median duration
nine years) as compared to patients with short-term (median duration
one year) rhinitis (median flow: 466 mL/sec) (P  0.0001).
CONCLUSION: This study provides the first evidence that pa-
tients with PER may show a progressive worsening of nasal
airflow depending on the duration of the disorder.
© 2008 American Academy of Otolaryngology–Head and Neck
Surgery Foundation. All rights reserved.
Allergic rhinitis (AR) is characterized by typical symp-toms, the most important being nasal obstruction,
which is dependent on allergic inflammation. Nasal obstruc-
tion may be roughly evaluated subjectively, by the percep-
tion of air passage throughout the nose, and objectively, by
measuring nasal airflow by rhinomanometry.1 It has been
evidenced that allergic inflammation markers, such as Th2-
type cytokines and nasal eosinophils, correlate well with
limited nasal airflow. AR has been recently reclassified by
the ARIA (Allergic Rhinitis and its Impact on Asthma)
workshop.2 The new classification of “intermittent” (ITR)
and “persistent” (PER) considers the duration of symptoms
(days/week and consecutive weeks), the symptom severity
(mild or moderate-severe), and the impact on quality of life.
AR is a common chronic disorder and is frequently
associated with asthma, as underlined by the same ARIA
document.2 It is well accepted that several structural
changes, including epithelial disruption, goblet cell hyper-
plasia, mucus gland hypertrophy, enhanced airway collagen
deposition, airway myofibroblast transformation, increased
matrix protein deposition, and smooth muscle hypertrophy
Received December 13, 2007; revised March 11, 2008; accepted March
24, 2008.
0194-5998/$34.00 © 2008 American Academy of Otolaryngology–Head and Nec
doi:10.1016/j.otohns.2008.03.027and hyperplasia, marked asthma are encompassed within
the term airway remodeling.3 However, two recent reviews
pointed out the paucity of studies concerning the evaluation
of structural changes in patients with AR.4,5 The main
aspects thus far considered have been: epithelium, reticular
basement membrane, and matrix proteins.
Regarding epithelial impairment, an electron micro-
scopic study revealed epithelial damage and torn tight junc-
tions of the epithelial cells in the nasal mucosa of allergic
patients.6 Moreover, patients with seasonal AR had a
thicker epithelium than normal subjects outside of the pol-
len season.7 During pollen season, marked goblet cell hy-
perplasia was present in AR patients, whereas metaplasia
and ciliated cell dysplasia were present throughout the
year.8 However, another study provided negative findings in
the same setting.9 Whereas in patients with perennial AR,
epithelial cell metaplasia was observed in nasal biopsy spec-
imens,10 in addition, reticular basement membrane impair-
ment, such as pseudothickening, caused by collagen and
fibrous protein deposition, even though to a lesser extent than
in asthma, has been reported in AR.11 Finally, matrix metal-
loproteinase 9 was increased after positive nasal allergen chal-
lenge.12
In contrast with these findings, a recent study did not
reveal any structural changes in the nasal mucosa of allergic
patients despite the presence of inflammatory cells.13 In-
stead, other studies have looked more at chronic rhinosinus-
itis (CRS). One study evidenced that the histopathologic
findings of asthma, namely heterogeneous eosinophilic in-
flammation and features of airway remodeling, are also
present in CRS.14 These findings, coupled with the coexist-
ence of common clinical features for both diseases, suggest
that the same pathologic disease process is manifest, pre-
senting as CRS in the sinonasal tissue and as asthma in the
lower airway. Sobol et al demonstrated that the sinus mu-
cosal inflammatory profile was similar in adults and chil-
dren with chronic sinusitis.15 However, the degree of tissue
eosinophilia and remodeling was significantly greater in
adult sinus specimens when compared with those of chil-
dren with chronic sinusitis.k Surgery Foundation. All rights reserved.
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did not investigate functional changes as a consequence of
nasal remodeling. Therefore, the purpose of this cross-sec-
tional study was to evaluate nasal function, ie, the nasal
airflow, in a cohort of patients with PER.
MATERIALS AND METHODS
Study Design
One hundred patients with PER were prospectively and
consecutively evaluated. The mean age was 22.8 years (SD,
5.0) with a minimum age of 18 and a maximum of 40 years.
The mean rhinitis duration was 5.9 years (SD, 5.5). All
subjects were naval seamen who were referred to the Naval
Medical Service, La Spezia, Italy for a mandatory periodic
visit. The Navy Medical Service Institutional Review Board
approved the study and written informed consent was ob-
tained from each subject. A detailed clinical history was
taken and complete physical examination, nasal endoscopy,
and rhinomanometry were performed on all patients.
For enrollment in the study, patients were required to
have: 1) a diagnosis of PER, 2) moderate or severe nasal
obstruction, as described below, and 3) duration of symp-
toms less than two years or greater than six years. Patients
reporting concomitant or one or more past asthma symptoms
(including persistent cough, wheezing, dyspnea, and shortness
of breath, either diurnal or nocturnal) were excluded to obtain
a homogeneous cohort. Subjects with acute upper respiratory
infections, anatomic nasal disorders (ie, significant septum
deviation), or nasal polyps, and patients using nasal or oral
corticosteroids or decongestants, antileukotrienes, and antihis-
tamines within the previous four weeks were also excluded.
The diagnosis of PER was made on the basis of a history
of nasal symptoms and positive skin prick test according to
validated criteria.2
Subjects
Patients were recruited on the basis of the disease duration:
the first group included patients with short-term rhinitis
(with a disease duration shorter than or equal to two years)
(n  50) and the second group included patients with
long-term rhinitis (with a disease duration longer than or
equal to six years) (n  50). We theoretically hypothesized
that a short duration would not determine relevant structural
alterations, whereas a longer duration could cause them.
Symptoms
Nasal obstruction symptom was assessed through a medical
questionnaire and evaluated on the following scale: 0 
absent, 1  mild (symptom was present but was not annoy-
ing or troublesome), 2  moderate (symptom was fre-
quently troublesome but did not interfere with either normal
daily activity or sleep), and 3  severe (symptom was
sufficiently troublesome to have interfered with normal
daily activity or sleep).Skin Prick Tests
The test was performed as stated by the European Academy of
Allergy and Clinical Immunology.16 The panel consisted of:
house dust mites (Dermatophagoides farinae and pteronyssi-
nus), cat, dog, grasses mix, Compositae mix, Parietaria offi-
cinalis and judaica, birch, hazel, olive tree, Alternaria tenuis,
Cladosporium, and Aspergilli mix (Stallergenes, Milan, Italy).
Rhinomanometry
Nasal airflow was measured by active anterior electronic
rhinomanometry (ZAN 100 Rhino Flow Handy II, ZAN,
Messgeraete Gmbh, Germany) according to validated crite-
ria.17 Nasal airflow was considered as the sum of recorded
airflow through the right and left nostrils, measured in
milliliters per second at a pressure difference of 150 Pa
across the nasal passage.
Statistical Analysis and Data Definitions
Descriptive statistics were first performed; qualitative pa-
rameters were reported as percentages with exact binomial
95% confidence intervals (95% CI) and quantitative param-
eters were reported as medians with first and third quartiles;
95% confidence intervals of group differences have been
calculated and reported either for qualitative variables or for
quantitative parameters. Comparison between qualitative
parameters was performed by the 2 test. A comparison of
quantitative variables between the two groups of subjects
(patients with short-term vs long-term rhinitis) was made by
means of the nonparametric Mann-Whitney U test since the
parameters were not normally distributed. Correlations be-
tween nasal airflow and rhinitis duration were made by
means of the nonparametric Spearman’s correlation coeffi-
cient (rs). All tests were two-sided and a P value less than
0.05 was considered statistically significant. The package
“Statistica release 6” (StatSoft Corp., Tulsa, OK) was used
for all analyses.
RESULTS
One hundred patients, 50 with short-term and 50 with long-
term rhinitis, were included in the study. A complete descrip-
tion of the two groups of patients is reported in Table 1. The
two groups were homogeneous for gender, sensitization (all
patients were sensitized to Dermatophagoides, and 76% of
the first group (95% CI: 62%-87%) and 70% of the second
(95% CI: 55% to 82%) were also positive for pollens; P 
0.50; difference between the groups: 6% and 95% CI of the
2 groups difference: from 11.4% to 23.4%), and overall
age.
The median rhinitis duration was one year in the short-
term group. In contrast, it was nine years in the long-term
group, with a significant difference between the two groups
(P  0.0001). The percentage of patients with a severe
obstruction score (score  3) was significantly higher
(72%) in the long-term rhinitis group as compared to the
727Ciprandi et al Relationship between rhinitis duration and . . .short-term group (44%) (P  0.0046), as reported in Table
1. Consequently, the percentage of patients with a moderate
obstruction score (score  2) was significantly higher
(56%) in the short-term rhinitis group as compared to the
long-term group (28%) (P  0.0046). This statistically
significant difference has also been demonstrated by the
95% CI of the group difference that does not include the
value of zero (95% CI of the group difference: 9.6% to
46.6%).
As shown in Table 1 and Figure 1, nasal airflow values
were significantly lower (median flow: 348 mL/sec) in pa-
tients with long-term rhinitis as compared to patients with
short-term rhinitis (median flow: 466 mL/sec) (P 0.0001).
There was a slight inverse correlation between rhinitis
duration and nasal airflow (rs  0.37; P  0.001). Nasal
airflow was significantly lower (median, 327 mL/sec; first to
third quartiles: 301 to 405 mL/sec) in patients with severe
obstruction with respect to patients with moderate obstruc-
tion (median, 485 mL/sec; first to third quartiles: 461 to 516
mL/sec) (Mann-Whitney U test; P  0.0001). Disease du-
ration was significantly lower (median, two years; first to
third quartiles: one to six years) in patients with moderate
obstruction with respect to patients with severe obstruction
(median, eight years; first to third quartiles: two to 10 years)
(Mann-Whitney U test; P  0.0009).
DISCUSSION
Allergic rhinitis is characterized by an inflammatory re-
sponse that increases the frequency of symptom occurrence.
In particular, nasal obstruction constitutes the most common
symptom resulting from allergic inflammation, and may be
considered the key symptom in patients with AR.18 Nasal
Table 1
Demographic and clinical parameters of the study pati
Gender: males, n (%)
Difference in percentages of males and 95% CI of
the group difference
Age (yrs): median
Mean difference and 95% CI of the group difference
Rhinitis duration (y): median
Mean difference and 95% CI of the group difference
Obstruction score: moderate, n (%)
Obstruction score: severe, n (%)
Difference in percentages of patients with moderate
obstruction and 95% CI of the group difference
Nasal airflow (mL/sec): median
Mean difference and 95% CI of the group difference
Figures in round parentheses are percentages calculated o
Figures in squared parentheses represent first and third quartobstruction may be evaluated both subjectively by scoringsymptoms and objectively by assessing airflow with rhino-
manometry.2 The limitation of the nasal airflow may be
reversible to decongesting and the degree of recovery is
associated with inflammatory grade; consequently, severe
inflammation is characterized by a poor response to this
test.18
Allergic inflammation is dependent on allergen exposure
even though symptoms may not appear; this phenomenon is
referred to as minimal persistent inflammation.19 The cas-
cade of chronic inflammatory events determines the occur-
rence of structural changes, and is more evident in the lower
airways.
Some recent reviews have analyzed the features of air-
way remodeling in AR.4,5 Epithelial disruption and desqua-
mation are infrequently observed in the nasal epithelium of
patients with AR. Moreover, it seems that there is some
Figure 1 Nasal airflow values in long-term and in short-term
ort-term rhinitis
(n  50)
Long-term rhinitis
(n  50) P
35 (70%) 37 (74%) 0.66
4% (13.6%–21.6%)
22 [20–24] 21 [20–22] 0.72
0.5 (2.5–1.5)
1 [1–2] 9 [8–12] 0.0001
8.9 (7.7–10.2)
28 (56%) 14 (28%) 0.0046
22 (44%) 36 (72%)
28% (9.4%–46.6%)
466 [398–494] 348 [302–419] 0.0001
77.9 (44.0–111.8)
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728 Otolaryngology–Head and Neck Surgery, Vol 138, No 6, June 2008pseudo-thickening of the reticular basement membra
caused by collagen and fibrous protein deposition, but 
lesser extent than in asthma.6 Regarding blood vessels, tw
recent studies have provided evidence of increased exp
sion of angiogenic markers in patients with pollen AR20,21
In addition, it has been recently reported that, in AR
tients, matrix metalloproteinases (MMPs) MMP-2 a
MMP-9 are the major proteolytic enzymes that induce n
airway remodeling.22 These enzymes are also important 
the migration of inflammatory cells through basement m
brane components. Furthermore, models of chronic infla
mation also reveal the participation of platelets in t
remodeling events, whereas platelet depletion was found
be more effective in suppressing airway remodeling 
cesses than the administration of glucocorticosteroids23
This process of destruction and repair of airway t
architecture is perhaps enhanced by platelet activation. 
gardless, the most recent review concludes that airway
modeling exists in rhinitis, but it seems to be far
extensive than in asthma.4,5 On the other hand, unlike 
asthma model, no study has investigated the possible f
tional consequences of nasal remodeling in AR and th
fore no relationship between nasal airflow and airway
modeling has previously been demonstrated.
Considering the evidence provided by a recent study
the duration of AR is a relevant risk factor for 
worsening as well as house dust mite sensitization,24 this
study aimed to evaluate the effect of AR duration on 
function, ie, nasal airflow, in two cohorts of patients
short-term and long-term) with PER alone. Indeed, the 
pose of the study was to evaluate whether the well-k
features of airway remodeling seen in patients with as
could also determine impairment of nasal airflow in A
The first finding shows that the duration of PER 
involve a more consistent and significant percentage
patients with severe obstruction. Consequently, a signific
diminution in nasal airflow is observed in patients 
long-term PER. This issue represents the most rele
finding of the study. It appears evident that PER dur
may determine a worsening of nasal function involving
air passages throughout the nasal cavities.
In addition, this finding was reinforced by evidence 
there was a slight inverse correlation between rhinitis d
tion and nasal airflow, and disease duration was sig
cantly lower in patients with moderate obstruction w
respect to patients with severe obstruction. Nasal airfl
was, furthermore, significantly lower in patients with se
obstruction with respect to patients with moderate obst
tion.
A possible explanation for this phenomenon might be
persistence of allergic inflammation, typical of PER19
Chronic inflammation may cause a characteristic anato
feature: the hypertrophy of turbinates. Hypertrophic tu
nates are very frequently observable in AR patients.24,25
The obvious consequence of turbinate enlargement is 
reduction of nasal cavities, which in turn causes a limitationin airflow. Therefore, this study underscores the releva
of progressive nasal airflow worsening that might depen
chronic inflammation, which in turn may determine st
tural alterations.
As in asthma, poor response to bronchodilators 
indicate airway remodeling; a reduced response to dec
gestants could also have the same significance in AR.
liminary findings of another study conducted in AR pat
would seem to support this idea, as a progressive redu
of nasal airflow reversibility significantly depends on d
tion of the disorder (manuscript in preparation).
In conclusion, this study provides the first evidence 
patients with PER may show a progressive worsenin
nasal airflow depending on the duration of the diso
Further studies should be addressed to correlate this f
tional issue with morphostructural changes.
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